Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease

    Research output: Contribution to journalEditorialResearchpeer-review

  2. Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of Infective Endocarditis in Patients with End Stage Renal Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diabetes increases the risk of bone fractures in patients on kidney replacement therapy: A DANISH national cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diurnal variation of magnesium and the mineral metabolism in patients with chronic kidney disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Long-term prognosis following hospitalization for acute myocarditis - a matched nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND OBJECTIVES: Serum calcification propensity is a novel functional test that quantifies the functionality of the humeral system of calcification control. Low serum calcification propensity is associated with higher risk of cardiovascular events and death in patients with ESKD. Increasing magnesium in serum increases (i.e., improves) serum calcification propensity in vitro, but so far, no clinical trials have investigated whether increasing serum magnesium increases serum calcification propensity in subjects with ESKD.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a single-center, randomized, double-blinded, parallel group, controlled clinical trial, in which we examined the effect of increasing dialysate magnesium from 1.0 to 2.0 mEq/L for 28 days compared with maintaining dialysate magnesium at 1.0 mEq/L on serum calcification propensity in subjects undergoing hemodialysis for ESKD. The primary end point was the value of calcification propensity, measured by T50, at the end of the intervention.

RESULTS: Fifty-nine subjects were enrolled in the trial, and of these, 57 completed the intervention and were analyzed for the primary outcome. In the standard dialysate magnesium group, serum calcification propensity was 233±81 minutes (mean±SD) at baseline (mean of days -7 and 0) and 229±93 minutes at follow-up (mean of days 21 and 28), whereas in the high dialysate magnesium group, serum calcification propensity was 247±69 minutes at baseline and 302±66 minutes at follow-up. The difference in serum calcification propensity between the two groups at follow-up (primary analysis) was 73 minutes (between-group difference; 95% confidence interval, 30 to 116; P<0.001), and the between-group difference in serum magnesium was 0.88 mg/dl (95% confidence interval, 0.66 to 1.10; P=0.001).

CONCLUSIONS: Increasing dialysate magnesium increases serum calcification propensity in subjects undergoing maintenance hemodialysis.

PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_08_21_CJASNPodcast_18_9_B.mp3.

Original languageEnglish
JournalClinical journal of the American Society of Nephrology : CJASN
Volume13
Issue number9
Pages (from-to)1373-1380
ISSN1555-9041
DOIs
Publication statusPublished - 2018

ID: 55070969